1. Pink Sheet
  2. >>Market Access

HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether

 
• By Jessica Merrill

Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.

United States Secretary of Health and Human Service, Alex Azar, speaks at the FT Pharma Pricing and Value Summit in New York
HHS Secretary Alex Azar at the FT Pharma Pricing and Value Summit • Source: FT Live

HHS Secretary Alex Azar reaffirmed that drug rebate changes are coming, during an address at the FT Pharma Pricing and Value Summit Sept. 13, but he did not mention eliminating discounts altogether.

The pharmaceutical industry is in a whirlwind about rebates, preparing for a future that is expected to include big changes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Defining Unmet Medical Need: EU Debate Sparks Concern Over Innovation And Access

 
• By Francesca Bruce

Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.

‘Urgent Need’ To Scale Up Advice Slots Under EU HTA Regulation – EUCOPE

 
• By Eliza Slawther

European regulators could investigate alternative ways of offering early advice to companies in relation to the Health Technology Assessment Regulation, given that official scientific advice slots are limited, a senior figure at EUCOPE says.

Oz Hints That Medicare Action On GLP-1s And Weight Loss Coming

 
• By Sarah Karlin-Smith

CMS Administrator Oz punted on a GLP-1 question in an interview, suggesting it was because his agency will be acting soon.

GLOBE Medicare Pricing Model: MFN Bargaining Chip Or Part Of Broad Reform Agenda?

 
• By Cathy Kelly

For manufacturers, the model could lead to a substantial reductions in prices for high cost physician administered drugs in Medicare, Medicaid and the 340B program.

More from Pink Sheet

EU Pharma Package: Keep Patients Front & Center In Defiing Unmet Medical Need

 
• By Francesca Bruce

EU trilogs on the new pharmaceutical legislation will finalize the role patients will take in influencing the development of a new definition of unmet medical need.

CDC Should Boost Vaccine Monitoring Transparency, Communication - National Academies Report

 
• By Sue Sutter

The Immunization Safety Office leveraged a “coordinated network of complementary surveillance systems” to monitor COVID-19 vaccine risks during the pandemic, but its communications faced challenges and were often intertwined with CDC efforts to promote vaccination, NASEM report finds.

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By Cathy Kelly

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.